* Phoenix International Life Sciences, of Saint Laurent,Canada, acquired the Clinical Research Center, of Laval,Canada, for $500,000 (Canadian), $1 million worth ofPhoenix shares and other considerations. Phoenix is acontract research organization. The company said it hasexpanded its Phase II through Phase IV studies businesswith the purchase of the Clinical Research Center, whichspecializes in advanced clinical development services.

* SuperGen Inc., of Emeryville, Calif., said it receivedorphan drug status from the FDA for an aplastic anemiatreatment, RF 1017. The drug is a human hormonederivative being evaluated in Phase I/II trials.

* T Cell Sciences Inc., of Needham, Mass., said initialclinical trials of TP10 showed the compound reducedcomplement activation in patients with acute lunginjuries. TP10 is a soluble version of a receptor on redblood cells. By inhibiting a complement response, thedrug is designed to prevent the unleashing of cell-destroying enzymes, which when produced in excess cancause dangerous inflammation associated with suchdisorders as cardiac reperfusion, transplant rejection andrespiratory ailments. Phase II trials of TP10 are expectedto begin in 1996 for adult respiratory distress syndrome.

* Lidak Pharmaceuticals Inc., of La Jolla, Calif., raised$9 million in the first stage of a planned $15 millionfinancing. The company sold $1.5 million in commonstock and $7.5 million of two-year convertible notes totwo institutional investors. The per-share price of thenotes will be determined at the time of conversion.

(c) 1997 American Health Consultants. All rights reserved.